Angiogenic Biomarkers in Preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Reproductive Biology

Background:

• Preeclampsia significantly increases maternal and neonatal morbidity and mortality globally.
• Angiogenic imbalance, a key factor in preeclampsia, often precedes clinical symptoms.
• Placenta-derived angiogenic biomarkers, soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), are crucial for early detection.

Conclusions:

• The sFlt-1/PlGF assay represents a significant advancement in the prediction and management of preeclampsia.
• Clinical implementation of the sFlt-1/PlGF ratio can optimize patient care and reduce adverse outcomes.
• This biomarker ratio is a valuable adjunctive measure in the clinical setting for preeclampsia.